Table 4.
Univariate and multivariate logistic regression analyses for risk factors associated with grade 4 neutropenia.
| Variable | Univariate | Multivariate (SMI) | Multivariate (SAT) | Multivariate (VAT) | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| SMI | ||||||||
| < 48.6 cm2/m2 | 1 | 1 | ||||||
| ≥ 48.6 cm2/m2 | 0.214 (0.057–0.658) | 0.012 | 0.221 (0.052–0.765) | 0.025 | ||||
| SAT | ||||||||
| < 226.6 cm2 | 1 | 1 | ||||||
| ≥ 226.6 cm2 | 0.920 (0.309–2.575) | 0.876 | 1.557 (0.412–6.024) | 0.512 | ||||
| VAT | ||||||||
| < 45.5 cm2 | 1 | 1 | ||||||
| ≥ 45.5 cm2 | 0.824 (0.265–2.877) | 0.745 | 1.437 (0.395–6.197) | 0.600 | ||||
| Age (years) | 0.956 (0.891–1.020) | 0.186 | ||||||
| BMI (kg/m2) | 0.863 (0.717–1.017) | 0.095 | 0.925 (0.746–1.131) | 0.460 | 0.835 (0.663–1.019) | 0.099 | 0.855 (0.696–1.022) | 0.106 |
| AJCC stage | 2.486 (1.270–5.159) | 0.010 | 2.267 (0.299–17.248) | 0.422 | 1.905 (0.253–13.973) | 0.524 | 2.422 (0.317–18.503) | 0.387 |
| T stage | 2.668 (1.276–5.940) | 0.011 | 1.619 (0.409–6.590) | 0.488 | 1.955 (0.469–8.684) | 0.360 | 1.662 (0.419–6.899) | 0.469 |
| N stage | 1.542 (0.943–2.519) | 0.079 | 0.867 (0.286–2.670) | 0.799 | 0.805 (0.281–2.319) | 0.682 | 0.758 (0.259–2.245) | 0.610 |
| Histologic grade | 1.229 (0.646–2.446) | 0.539 | ||||||
| HR status | ||||||||
| ER positive | 1.114 (0.386–3.515) | 0.846 | ||||||
| PR positive | 0.545 (0.194–1.496) | 0.240 | ||||||
| HER2 positive | 0.457 (0.120–1.420) | 0.203 | ||||||
| Surgery type | ||||||||
| Total mastectomy | 1 | |||||||
| Partial mastectomy | 0.416 (0.133–1.173) | 0.109 | ||||||
| Hormonal therapy | 0.641 (0.212–2.079) | 0.437 | ||||||
| Radiotherapy | 1.556 (0.547–4.868) | 0.422 | ||||||
| Targeted therapy | 2.118 (0.402–9.555) | 0.336 | ||||||
Multivariate logistic regression included variables with a P < 0.10 from the univariable analysis, as well as SMI, SAT, and VAT regardless of their P in the univariable analysis.
SMI skeletal muscle index, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, BMI body mass index, AJCC American Joint Committee on Cancer, HR hormone receptor, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2.